- Home
- TBRG vs RCEL Comparison
TBRG vs RCEL Comparison
Compare TBRG & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- RCEL
- Stock Information
- Founded
- TBRG 1979
- RCEL 2020
- Country
- TBRG United States
- RCEL United States
- Employees
- TBRG N/A
- RCEL N/A
- Industry
- TBRG
- RCEL Medical/Dental Instruments
- Sector
- TBRG
- RCEL Health Care
- Exchange
- TBRG NYSE
- RCEL Nasdaq
- Market Cap
- TBRG 271.5M
- RCEL 308.6M
- IPO Year
- TBRG N/A
- RCEL N/A
- Fundamental
- Price
- TBRG $23.34
- RCEL $8.73
- Analyst Decision
- TBRG Buy
- RCEL Buy
- Analyst Count
- TBRG 3
- RCEL 5
- Target Price
- TBRG $14.67
- RCEL $18.00
- AVG Volume (30 Days)
- TBRG 90.5K
- RCEL 251.2K
- Earning Date
- TBRG 02-27-2025
- RCEL 02-13-2025
- Dividend Yield
- TBRG N/A
- RCEL N/A
- EPS Growth
- TBRG N/A
- RCEL N/A
- EPS
- TBRG N/A
- RCEL N/A
- Revenue
- TBRG $337,674,000.00
- RCEL $60,040,000.00
- Revenue This Year
- TBRG $1.02
- RCEL $36.71
- Revenue Next Year
- TBRG $6.06
- RCEL $54.48
- P/E Ratio
- TBRG N/A
- RCEL N/A
- Revenue Growth
- TBRG 0.26
- RCEL 32.24
- 52 Week Low
- TBRG $7.55
- RCEL $7.51
- 52 Week High
- TBRG $23.64
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- TBRG 83.06
- RCEL 31.80
- Support Level
- TBRG $20.62
- RCEL $8.53
- Resistance Level
- TBRG $23.32
- RCEL $9.42
- Average True Range (ATR)
- TBRG 0.82
- RCEL 0.65
- MACD
- TBRG 0.19
- RCEL -0.39
- Stochastic Oscillator
- TBRG 93.96
- RCEL 3.89
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.